膜杰作
Star Staining
分子别名（Synonym）
HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQV)
表达区间及表达系统（Source）
APC-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (HL1-HA2H8) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLMWITQV peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769-1 (B2M) & SLLMWITQV).
Predicted N-terminus: Gly 25 & Ser
Request for sequence
蛋白结构（Molecular Characterization）
APC-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein is assembled by biotinylated monomer and APC-labeled streptavidin.
Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein is produced by co-expression of HLA and B2M loaded with NY-ESO-1 peptide. Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
偶联（Conjugate）
APC
Excitation Wavelength: 640 nm
Emission Wavelength: 661 nm
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in 0.2% BSA with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
活性（Bioactivity）-FACS
5e5 of NY-ESO-1 specific TCR-HEK293 cell line were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (Cat. No. HL1-HA2H8) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).
Protocol
背景（Background）
NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*0201 NY-ESO-1 (SLLMWITQV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NY-ESO-1.
